These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24563621)

  • 1. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
    Chen CS; Doloff JC; Waxman DJ
    Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
    Wu J; Waxman DJ
    Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
    Wu J; Jordan M; Waxman DJ
    BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
    Doloff JC; Waxman DJ
    Cancer Res; 2012 Mar; 72(5):1103-15. PubMed ID: 22237627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
    Doloff JC; Chen CS; Waxman DJ
    Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
    Doloff JC; Waxman DJ
    BMC Cancer; 2015 May; 15():375. PubMed ID: 25952672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
    Wang R; Qin S; Chen Y; Li Y; Chen C; Wang Z; Zheng R; Wu Q
    Oncol Rep; 2012 Aug; 28(2):439-45. PubMed ID: 22641525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
    Wu J; Waxman DJ
    Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
    Ma J; Waxman DJ
    Mol Cancer Ther; 2008 Jan; 7(1):79-89. PubMed ID: 18202011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model.
    Ishida T; Shiraga E; Kiwada H
    J Control Release; 2009 Mar; 134(3):194-200. PubMed ID: 19095022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.
    Doloff JC; Khan N; Ma J; Demidenko E; Swartz HM; Jounaidi Y
    Curr Cancer Drug Targets; 2009 Sep; 9(6):777-88. PubMed ID: 19754361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
    Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
    Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
    Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
    Du B; Waxman DJ
    Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.
    Emmenegger U; Shaked Y; Man S; Bocci G; Spasojevic I; Francia G; Kouri A; Coke R; Cruz-Munoz W; Ludeman SM; Colvin OM; Kerbel RS
    Mol Cancer Ther; 2007 Aug; 6(8):2280-9. PubMed ID: 17671082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.
    Jia L; Waxman DJ
    Cancer Lett; 2013 Apr; 330(2):241-9. PubMed ID: 23228633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.